Royal Philips Electronics (NYSE: PHG, AEX: PHI) today introduced the HomeLox portable liquid oxygen system. The innovative system enables oxygen users to generate and store the liquid form of oxygen in the home setting. The HomeLox system offers users the long-lasting and lightweight characteristics of traditional liquid systems, while freeing them from difficulties of filling and dependence on deliveries associated with conventional systems.
Home oxygen is a critical, life-sustaining medical treatment prescribed to nearly 1.5 million Medicare patients annually who suffer from respiratory illnesses such as chronic obstructive pulmonary disease (COPD).
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/philips/45648/
Thirty-six million Americans suffer from migraines, leading to more than $20 billion in medical expenses and costs related to lost productivity each year¹. In recognition of National Migraine Awareness Month and the significant unmet medical needs of migraine patients, Zogenix, Inc. (NASDAQ: ZGNX) is highlighting the importance of selecting the appropriate medication for a patient’s “treatment toolbox” to address specific types of migraine episodes.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/zogenix/50344/
On June 5, CVS/pharmacy kicked-off its 10th annual in-store fundraising campaign -- “Researching a Cure” -- to support the fight against amyotrophic lateral sclerosis (ALS). Funds raised through the campaign benefit the ALS Therapy Alliance (ATA), a leading organization dedicated to advancing ALS research. Through the Researching a Cure campaign, CVS/pharmacy has raised more than $23 million in its stores and online at www.cvs.com, to fund new clinical research with the aim of discovering a treatment or cure for ALS. The 2011 campaign will run through June 25.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/cvs/50475/
Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced today that the U.S. Food and Drug Administration (FDA) has approved the company’s antibacterial drug DIFICID™ (fidaxomicin) tablets for the treatment of Clostridium difficile-associated diarrhea (CDAD) in adults 18 years of age and older. CDAD is a significant medical problem in hospitals and long-term care facilities, and is beginning to emerge in the community among people previously at low risk for the disease. In the largest Phase 3 clinical studies ever conducted in CDAD, DIFICID had clinical response rates at the end of treatment that were non-inferior to oral vancomycin. DIFICID was superior to vancomycin in sustaining clinical response through 25 days beyond the end of treatment. DIFICID is the only FDA-approved antibacterial drug proven to be superior to vancomycin in sustained clinical response for CDAD.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/optimerpharma/50177/
As many as one in five U.S. teens suffers from disabling mental illness. Throughout Mental Health Awareness Month in May, BeSmartBeWell.com highlights the issue of mental illness in teens and tells the stories of two teens who moved from diagnosis through treatment and recovery.
What does mental illness look like in teens? It looks like Colleen, who’s battled depression and anxiety since she was 13, and Katie, who struggled with addiction in her early teens. Mental illness in teens looks just like the kid next door – studies show nearly half of all youth will experience a mental disorder at some point in their lives.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/besmartbewell/50033/
EDAP TMS SA (Nasdaq: EDAP), the global leader in therapeutic ultrasound, announced today that new 10 year data from an international registry-based multi-center study shows 83 percent of patients had no biopsy evidence of disease after treatment with Ablatherm® HIFU, supporting the technology as a standard primary treatment for localized prostate cancer. Study results were presented at the American Urological Association (AUA) 2011 Annual Meeting, Washington, D.C.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/edap/49862/
The American Pain Foundation (APF) announced today the launch of new information and resources on pain medication safety for acetaminophen and nonsteroidal anti-inflammatory drugs (NSAIDs) as a part of its PainSAFE™ educational initiative. The new information will be launched with a national public service announcement (PSA) emphasizing the safe use of pain treatment options, particularly medications containing NSAIDs (aspirin, ibuprofen, naproxen) and acetaminophen (Tylenol, APAP). APF is the nation’s largest consumer advocacy organization dedicated to people with pain.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/painfoundation/49865/
Instant improvements and no recovery time make the new ARTISTRY® intensive skincare renewing peel a convenient, at-home alternative to acid-based peels. It provides a gentle, one-step option that’s cost-effective and rivals benefits experienced from professional treatments.
Intensive skincare renewing peel is appropriate for women of all skin types, including Miss America 2011 Teresa Scanlan. With traveling 20,000 miles a month, Scanlan simply doesn’t have time to regularly visit a dermatologist or wait for recovery from redness experienced after professional treatments. “I’ve turned to at-home alternatives. I love ARTISTRY intensive skincare renewing peel, which provides my skin with what I need in just minutes, without worrying about irritation,” comments Scanlan.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/artistrybeauty/48331/
Legacy®, through an unrestricted educational grant from Genentech, launches two new resources devoted to helping smokers understand their risks for lung cancer and reducing their risks for mortality.
Lung cancer is the nation's number one cancer killer of both men and women, accounting for 28 percent of all cancer deaths. More Americans are killed by lung cancer than by breast cancer, prostate cancer, or any other cancer. Up to 90 percent of lung cancer cases result from smoking and no current treatment can cure lung cancer. Early detection is the key to better quality and longevity of life.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/legacy/47244/
Go to http://www.manageyourtreatment.org for more information.
Cancer has touched the lives of all of us. Each year, it takes the lives of more than half a million Americans and seven million people worldwide.
Cynthia Nixon and Edie Falco will appear in this PSA to encourage cancer patients to win back some control in their lives by managing their treatment. In their role as the campaign ambassadors, Falco and Nixon appear to encourage people to better understand their options and provide support for managing their care.
Baylor University Medical Center at Dallas (Baylor Dallas) is now home to North Texas’ largest outpatient cancer center. The new Baylor Charles A. Sammons Cancer Center at Dallas opens to the public Saturday, March 26. The 467,000 square-foot facility marks a new era in cancer care for the Dallas-Fort Worth Metroplex and beyond by offering comprehensive services for cancer patients from initial diagnosis through post-recovery. Baylor Dallas, already the leading cancer care provider in North Texas in terms of patients treated and according to Consumer Choice data, now brings together multiple phases of cancer care under one roof.
To view Multimedia news Release, go to http://multivu.prnewswire.com/mnr/baylorhealth/47429/
Two of the most advanced tools for precise, radiotherapy-based treatment are now under one roof in Seattle. Swedish Medical Center this month became the first facility in the Pacific Northwest – and one of only a handful in North America – to open a unit that incorporates both CyberKnife and Gamma Knife technologies. The 3,950-square-foot Swedish Radiosurgery Center, formerly known as the Seattle CyberKnife Center, is located on the
